These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 26364606)

  • 21. That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.
    Sale MJ; Cook SJ
    Br J Pharmacol; 2013 Aug; 169(8):1708-22. PubMed ID: 23647573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik.
    Lopez J; Hesling C; Prudent J; Popgeorgiev N; Gadet R; Mikaelian I; Rimokh R; Gillet G; Gonzalo P
    Cell Death Differ; 2012 Sep; 19(9):1459-69. PubMed ID: 22388352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.
    Gysin S; Paquette J; McMahon M
    Mol Cancer Res; 2012 Dec; 10(12):1607-19. PubMed ID: 22833572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies.
    Yang L; Zheng L; Chng WJ; Ding JL
    Trends Pharmacol Sci; 2019 Nov; 40(11):897-910. PubMed ID: 31662208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
    Caunt CJ; Sale MJ; Smith PD; Cook SJ
    Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
    Ammoun S; Flaiz C; Ristic N; Schuldt J; Hanemann CO
    Cancer Res; 2008 Jul; 68(13):5236-45. PubMed ID: 18593924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The biology and clinical development of MEK inhibitors for cancer.
    Luke JJ; Ott PA; Shapiro GI
    Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
    Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
    Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Copper is required for oncogenic BRAF signalling and tumorigenesis.
    Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
    Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel mitogen-activated protein kinase kinase inhibitors.
    Chapman MS; Miner JN
    Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
    Sale MJ; Cook SJ
    Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics.
    Urasaki Y; Fiscus RR; Le TT
    Sci Rep; 2018 Jul; 8(1):9991. PubMed ID: 29968772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Raf kinase inhibitors in oncology.
    Strumberg D; Seeber S
    Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ghrelin prevents cardiac cell apoptosis during cardiac remodelling post experimentally induced myocardial infarction in rats via activation of Raf-MEK1/2-ERK1/2 signalling.
    Eid RA; Alkhateeb MA; Al-Shraim M; Eleawa SM; Shatoor AS; El-Kott AF; Zaki MSA; Shatoor KA; Bin-Jaliah I; Al-Hashem FH
    Arch Physiol Biochem; 2019 May; 125(2):93-103. PubMed ID: 29447000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
    Wu PK; Park JI
    Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
    Sale MJ; Cook SJ
    Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
    Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
    J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.